Innate immune cells in the pathophysiology of calcific aortic valve disease: lessons to be learned from atherosclerotic cardiovascular disease?

Wieteke Broeders1 · Siroon Bekkering1 · Saloua El Messaoudi2 · Leo A. B. Joosten1,3 · Niels van Royen2 · Niels P. Riksen1

Received: 21 February 2022 / Revised: 4 May 2022 / Accepted: 4 May 2022 / Published online: 17 May 2022
© The Author(s) 2022

Abstract
Calcific aortic valve disease (CAVD) is the most common valvular disease in the developed world with currently no effective pharmacological treatment available. CAVD results from a complex, multifactorial process, in which valvular inflammation and fibro-calcific remodelling lead to valve thickening and cardiac outflow obstruction. The exact underlying pathophysiology of CAVD is still not fully understood, yet the development of CAVD shows many similarities with the pathophysiology of atherosclerotic cardiovascular disease (ASCVD), such as coronary artery disease. Innate immune cells play a crucial role in ASCVD and might also play a pivotal role in the development of CAVD. This review summarizes the current knowledge on the role of innate immune cells, both in the circulation and in the aortic valve, in the development of CAVD and the similarities and differences with ASCVD. Trained immunity and clonal haematopoiesis of indeterminate potential are proposed as novel immunological mechanisms that possibly contribute to the pathophysiology of CAVD and new possible treatment targets are discussed.

Keywords Calcific aortic valve disease · Atherosclerotic cardiovascular disease · Inflammation · Innate immune cells · Trained immunity · Clonal haematopoiesis of indeterminate potential

Introduction
Calcific aortic valve disease (CAVD) is the most common type of valvular heart disease in the Western world and is characterized by valvular inflammation, fibrosis and calcification. It is the leading cause of aortic valve stenosis and, ultimately, it can cause angina, syncope, heart failure and sudden cardiac death [27]. One in four people over 65 years suffer from aortic valve sclerosis of which 10–15% progresses to aortic valve stenosis [114]. Once symptomatic, untreated patients have a poor prognosis with a 2- and 5-year survival rate of 50% and 25%, respectively [114]. CAVD has a major impact on health care and this is expected to increase in the coming decades due to the ageing population [16]. Currently, no effective pharmacological treatment is available to prevent CAVD or slow down disease progression.

Traditionally, the development of CAVD was seen as a passive, degenerative process, but nowadays it is increasingly recognized as an active, multifactorial process with an important role for activation of the innate immune system. Importantly, this process appears to have many similarities with the pathophysiology of atherosclerosis and the pathophysiological process underlying atherosclerotic cardiovascular disease (ASCVD), such as coronary artery disease (CAD) [19, 82]. However, the exact underlying pathophysiology of CAVD remains incompletely understood, which hampers target-specific development of pharmacotherapy.

In this review, we discuss the role of innate immune cells, and in particular the role of monocytes, in the development...
of CAVD, and its similarities and differences with ASCVD. After a brief comparison of the overall pathophysiology of CAVD and ASCVD, we discuss in detail the current knowledge on valvular and systemic inflammation and innate immune cells in the development and progression of CAVD and the pivotal role of oxidized lipids. For each component, we systematically compare its role in CAVD and ASCVD. Furthermore, we propose two novel immunological mechanisms that might contribute to innate immune system activation in CAVD, namely trained immunity and clonal hematopoiesis of indeterminate potential (CHIP). Finally, we discuss how this knowledge might deliver novel therapeutic targets for the treatment of CAVD.

**Summary of the pathophysiology of CAVD**

The aortic valve is tricuspid, although 1–2% of individuals have a bicuspid or even a unicuspid or quadricuspid valve. Aortic valve leaflets consist of valvular endothelial cells (VECs), valvular interstitial cells (VICs) and valvular extracellular matrix (VECM) [119]. VECs cover the leaflets and regulate valve permeability and homeostasis. The valvular interstitium is composed of three layers: the laminae fibrosa (aortic side), spongiosa and ventricularis. VICs are found throughout the interstitium and regulate valve remodelling via the synthesis and degradation of VECM components. VICs are quiescent and have characteristics similar to fibroblasts in the homeostatic state [115]. Furthermore, healthy valves contain few resident macrophages, mast cells and dendritic cells as well as a small number of myofibroblast-like cells [40, 113].

The current proposed pathophysiological process of CAVD is divided into an initiation and a propagation phase (Fig. 1) [3]. The initiation phase starts by damage and stimulation of the VECs, which can be initiated by oxidative or mechanical stress [113, 152]. As bicuspid and unicusp valves are subject to more mechanical stress, they often develop aortic valve stenosis one to two decades earlier [136]. The valvular damage alters the permeability and allows for infiltration of circulating lipoproteins, such as lipoprotein (a) (Lp(a)) and low-density lipoprotein (LDL) and immune cells, including monocytes and T lymphocytes [109, 111, 113]. Oxidized LDL (oxLDL) and Lp(a) stimulate and activate VICs and VECs, creating an inflammatory environment [111, 113] which further propagates the infiltration of immune cells [55]. The inflammatory milieu promotes VECs, VICs and macrophages to secrete extracellular vesicles, and induces apoptosis of macrophages and VICs, which release apoptotic bodies [72, 93]. Both processes cause microcalcifications by dystrophic calcification. Moreover, VICs are stimulated to differentiate into a myofibroblastic phenotype, causing VECM remodelling and fibrosis [25]. Further differentiation of myofibroblasts into an osteoblast-like phenotype results in biomineralization [58].

The propagation phase is characterized by accelerated fibrosis and calcification [102]. Accumulation of calcium and leaflet stiffening creates more mechanical stress and calcium deposition. A self-perpetuating cycle is established which eventually leads to narrowing of the valvular orifice [102, 177]. The valvular obstruction creates left ventricle systolic pressure overload, leading to myocardial hypertrophy, interstitial fibrosis and ultimately results in heart failure [82]. For the purpose of this review, we refer to excellent recent reviews for a more detailed general overview of the pathophysiology of CAVD [57, 72, 82, 115].

**CAVD and ASCVD, two sides of the same coin?**

The development of CAVD is increasingly considered to be an atherosclerosis-like process, especially in the initiation phase [38]. Both CAVD and ASCVD represent chronic inflammatory disorders, which involve initial endothelial damage and activation, lipid deposition, immune cell recruitment, inflammation, neoangiogenesis and calcification (Fig. 2) [38, 102]. Pathological studies show active remodelling processes regulated by inflammation in both ASCVD and CAVD [27]. Importantly, in atherosclerosis-prone apolipoprotein E-deficient (ApoE−/−) mice, atherosclerotic plaques develop first in the aortic valves and aortic root [54]. Furthermore, CAVD and CAD often co-exist [31, 74], are both slowly progressive conditions with precursor lesions that remain asymptomatic for some time and they share important risk factors, including increased age, male sex, cigarette smoking, hypertension, kidney disease, diabetes mellitus, obesity, hyperlipidaemia, elevated Lp(a) levels and shared genetic susceptibility loci [20, 27, 130, 138, 151].

The role of the innate immune system is well established in the pathophysiology of ASCVD. Monocyte-derived macrophages are the principal immune cell type in atherosclerotic plaques and are involved in its initiation, progression and destabilization [95]. Limiting the influx of circulating monocytes into the arterial wall in atherosclerosis-prone mice prevents atherosclerotic plaque formation [17]. In these ApoE−/− mice, the lesion size was reduced particularly in the valve leaflet region, where wild-type mice developed the most severe lesions [54]. Furthermore, targeting inflammation can prevent clinical atherosclerotic complications [139]. In addition, accumulating evidence points to the fact that circulating monocytes are characterized by an activated inflammatory phenotype in patients with established ASCVD or risk factors for ASCVD, including elevated LDL-cholesterol and Lp(a). Thus, activation of the innate immune system not only occurs in the inflammatory micro-environment of the

© Springer
plaque, but also in circulating monocytes [13, 14, 134, 163]. Moreover, recent studies have pointed out that the activation of innate immune cells in ASCVD also occur at the level of the myeloid progenitors in the bone marrow compartment [107, 164].

There are also important differences between CAVD and ASCVD, particularly in the advanced stages of the diseases. Firstly, there are patients with severe CAVD who do not suffer from advanced ASCVD and vice versa [62]. Secondly, statins do not prevent cardiovascular events in CAVD as opposed to their beneficial effect in patients with ASCVD, suggesting different pathophysiological processes [23, 48, 126]. Moreover, advanced lesions display histological differences, such as the fibrous cap and necrotic cores rich in foam cells in atheromas, which are not present in CAVD [89], and the limited presence of foam cells in calcified valves [71]. Lastly, adverse events in atherosclerosis are often related to plaque ruptures leading to acute coronary syndrome, while in CAVD, they are mostly caused by slowly progressive valve narrowing driven by progressive calcification [38, 90]. Despite the differences between CAVD and ASCVD, the profound commonalities in risk factors and similarities in (early) pathological features suggest overlap in pathophysiology, including a key role for inflammation and activation of the innate immune system. A systematic overview of the similarities and differences between CAVD and ASCD is given in Table 1.
CAVD, a chronic inflammatory disease

Inflammation in CAVD occurs on several levels. Besides local inflammation in the aortic valves, inflammation can be observed in the circulation, by activated immune cells and increased inflammatory proteins. In this section, we will describe the various components of the inflammatory process in CAVD, from local to systemic inflammation, and compare this to the situation in ASCVD.

Local valvular inflammation

CAVD develops by an active inflammatory process driven by infiltrated lipoproteins and immune cells. Histopathological examination of human calcified aortic valves shows subendothelial thickening with lipid deposition, immune cell infiltration (predominantly macrophages and T lymphocytes) and mineralization in early CAVD lesions and more advanced lesions in further progressed CAVD [29, 89, 94, 111, 113]. The inflammatory infiltrates are associated with valvular remodelling, neovascularization and osseous metaplasia [29]. Moreover, calcified aortic valves show an upregulated expression of multiple proinflammatory cytokines in total valve tissue, including interleukin (IL)-1β, IL-6, tumour necrosis factor (TNF), anti-inflammatory cytokines, as IL-10, and transforming growth factor (TGF)-β, as well as chemokines such as chemokine C-X-C ligand (CXCL) 5, CXCL9, chemokine C–C ligand (CCL) 19 and CCL 21 as summarized in Raddatz et al. [118]. The expression of the anti-inflammatory cytokine IL-37 is downregulated in calcified aortic valves [172]. The cells contributing to this valvular inflammation will be discussed below.

Valvular endothelial damage

Early in CAVD development, altered haemodynamic forces on the valve affect the phenotype of VECs, leading to endothelial dysfunction. These altered forces result for
example from hypertension [83], by stiffening of the valvular tissue due to ageing [143, 165], or from increased oxidative stress. In addition, other risk factors, such as diabetes or dyslipidaemia could precipitate endothelial dysfunction. The relevance of VEC injury is demonstrated by histopathological studies showing lipoprotein accumulation mainly in regions of low shear stress [109]. In the aortic valve, the damaged VECs subsequently express adhesion molecules, stimulating the recruitment of immune cells [55]. These immune cells produce cytokines leading to further stimulation of VECs and the transition of VECs into VICs by endothelial to mesenchymal transition [84]. Furthermore,
VECs express endothelial nitric oxide synthase (eNOS), which regulates the production of nitric oxide. Calcified valves express reduced levels of eNOS, leading to increased oxidative stress which contributes to valvular inflammation by increasing lipoprotein oxidation [120, 153]. By these very processes, VECs promote inflammation, fibrosis and calcification.

This is comparable to the initiation phase in atherogenesis, where endothelial cell (EC) activation occurs in areas of disturbed shear stress, such as near arterial bifurcations, which permits circulating ApoB-containing lipoprotein and immune cells to enter the intimal space [81]. Stimulated ECs can also undergo endothelial to mesenchymal transition and migrate to the intima, where they can contribute to inflammation and intimal thickening [81]. Endothelial to mesenchymal transition is associated with atherosclerotic plaque instability [42].

**Valvular interstitial cells contribute to valvular inflammation**

VICs are the most abundant cells in the valvular tissue and transiently transition into myofibroblasts during normal hemodynamic stress on the valvular tissue to remodel the ECM. During CAVD progression, the transition into myofibroblasts is more persistent, leading to pathological fibrosis. Ultimately, the myofibroblasts can differentiate into an osteoblast-like phenotype, which promotes calcium deposition. Although the exact underlying process driving valvular fibrosis and calcification remains uncertain [77], it is clear that proinflammatory communication between VICS and immune cells plays an important role. Firstly, Toll-like receptors (TLRs), especially TLR-2 and -4, are upregulated in VICS in calcified aortic valves. Several pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) promote inflammation and osteogenesis by activating the nuclear factor-κB (NF-κB) pathway in VICS via TLR stimulation. This leads to the production of proinflammatory and pro-calcifying molecules [52]. Recently, it was demonstrated that the upregulation of TLR2 in VICS is enhanced through paracrine signalling of TNF by activated monocytes [174]. IL-37, which shows a lower expression in calcified valves, suppresses the production of proinflammatory mediators by human VICS after TLR stimulation [172, 173]. Secondly, the differentiation of VICS into myofibroblasts or osteoblast-like cells is stimulated by cytokines, including TGF-β1 [76] or TNF, IFN-γ, IL-6 and receptor activator of NF-κB ligand (RANKL) [51, 57, 65]. In addition, myofibroblasts upregulate the expression of lepin-like oxidized LDL receptor-1 and scavenger CD36 receptors, leading to uptake of oxidized lipids and production of inflammatory molecules, resembling the foam cell-forming potential of macrophages in atherosclerotic lesions [147]. Lastly, VICs promote calcification via apoptosis and osteogenesis [77].

The processes of valvular fibrosis and calcification by VICS differ substantially from the extracellular matrix remodelling that occurs in atherosclerotic plaques, in which local inflammation stimulates smooth muscle cells to form a fibrous cap that shields to growing necrotic core, and stimulates vascular calcification which is summarized in detail in other reviews [37, 81].

**Macrophages**

Macrophages are present in healthy valves, although histopathologic examination of explanted calcified valves demonstrates a higher abundance with CAVD progression [79, 113]. The majority of macrophages are located close to calcium deposits and areas of vascularization [99] and the inflammatory infiltrates are associated with active VECM remodelling, the severity of the stenosis and haemodynamic progression [29].

Macrophages are presumed essential in the initiation phase of CAVD (Fig. 1). After infiltration of circulating monocytes and differentiation into macrophages, the cells take up modified lipids via their scavenger receptors and can become foam cells [71, 111]. Calcified aortic valves contain only few foam cells, although fatty streaks are prominently found at the inflow and outflow surface of the valves [71]. In addition, macrophages are activated by cytokines and oxidized lipoproteins via pattern recognition receptors (PRRs) resulting in activation of the NF-κB pathway. Activated macrophages secrete multiple proinflammatory molecules, including IL-1β, IL-6, TNF, TGF-β, cathepsins, osteopontin and matrix metalloproteinases (MMPs) [47, 72]. The predominant macrophage subset found in human explanted calcified aortic valves consists of proinflammatory CD11c-positive macrophages [79] with an increased mRNA expression of iNOS, monocyte chemoattractant protein 1 (MCP-1), TNF, IL-6 and IL-12 [78]. In addition, the number of anti-inflammatory macrophages (CD206+) is lower compared to healthy valves [79]. Chronic inflammation arises as the macrophages stimulate VECs, VICs and other immune cells, thereby promoting further immune cell recruitment, apoptosis, myofibroblastic and osteogenic differentiation of VICs and the differentiation of VECs into VICs via endothelial to mesenchymal transition [57, 96].

In the propagation phase, macrophages contribute to accelerated valvular fibrosis and calcification [57, 72]. Fibrous VECM remodelling is dependent on fibrosis and proteolysis. Activated macrophages produce TGF-β1, which in turn induces myofibroblastic differentiation of VICs [76] and secretes matrix remodelling proteins, such as MMPs, which promotes proteolysis.
Valvular calcification relies on two distinct processes; dystrophic calcification and biomineralization. Dystrophic calcification is defined by continuous deposition of microlacifications and hydroxyapatite by apoptotic macrophages and VICs and extracellular vesicles, and is responsible for most of the calcification [72, 93]. Biomineralization is induced by osteoblast-like VICs, resembling osteogenesis. Inflammatory communication might play an important role in the calcification potential of these VICs [58, 79]. Conditioned medium of proinflammatory macrophages deactivates myofibroblasts and stimulates their proliferation, which is attributed to TNF and IL-1β [58]. TNF and IL-6, also secreted by proinflammatory macrophages, stimulate osteogenic differentiation of VICs and upregulate the expression of osteogenic markers by VICs [58, 79]. Macrophages can also contribute to clearance of mineralization through osteoclastogenesis after stimulation by RANKL and macrophage colony-stimulating factor (M-CSF), produced by osteoblast-like cells and T lymphocytes [18, 33]. These osteoclast-like cells can be found in calcified aortic valves and express proteins involved in mineral uptake and bone resorption [93, 97]. However, interferon (IFN)-γ produced by activated T lymphocytes impairs this osteoclastic activity. As a result, the osteoclast-like cells cannot counterbalance the osteoblastic activity from the VICs [98]. These processes, orchestrated by macrophages, progressively increase valvular fibrosis and calcification. The role of the adaptive immune system in the development of CAVD is discussed in recent excellent reviews [10, 118].

The role of macrophages in ASCVD is well established and shows many similarities with the pathogenesis of CAVD (Table 1). Monocyte-derived macrophages are the main immune cell type found in the atherosclerotic plaque and play a central role in all stages of atherogenesis [95]. Proinflammatory stimuli within the atherosclerotic plaque stimulate the macrophages to produce multiple proinflammatory chemokines and cytokines, creating an inflammatory milieu [24, 145]. However, contrary to in CAVD, foam cells are abundant in the atherosclerotic plaque and are distributed randomly across the neointima [71]. During progression of the atherosclerotic plaque, the death of foam cells and macrophages and subsequent impaired clearance of apoptotic cells by phagocytic cells (efferocytosis), contribute to the formation of a lipid and necrotic core [69, 80]. Moreover, macrophages contribute to destabilization of the atherosclerotic plaque by producing proteases [103].

Oxidized lipids: central regulators of inflammation in CAVD

Lipoproteins take centre stage in the development and progression of CAVD by orchestrating the underlying inflammatory process. Observational studies and Mendelian randomization studies indicate that elevated LDL-cholesterol and Lp(a) levels are risk factors for CAVD [5, 7, 91, 137, 144]. Elevated Lp(a) levels are also associated with accelerated disease progression [7, 20, 176]. A single nucleotide polymorphism in the Lp(a) locus (rs1045872) is associated with elevated Lp(a) levels [7] and with aortic valve calcification [150]. Patients with mild to moderate CAVD with elevated Lp(a) levels suffer from a faster CAVD progression [21]. Lipids and lipid loaded macrophages localize predominantly in the subendothelial region of the fibrosa side of the valve [71, 111]. Valves containing higher amounts of oxLDL have denser inflammatory infiltrates, increased valvular tissue remodelling and higher expression of TNF [94]. The crucial role of lipoproteins is further demonstrated in the Reserva mouse model in which rapid normalisation of circulating cholesterol after a period of hyperlipidemia leads to a normalization of valvular oxidative stress, suppression of pro-osteoigenic signalling, and a prevention of disease progression [91].

Lp(a) and oxLDL are powerful stimuli that drive valvular inflammation and calcification by oxidized phospholipids (OxPL) (Fig. 1). Lp(a) is the major carrier of OxPL in the circulation[163]. Antigen-presentation of oxLDL and apoB can activate T lymphocytes that subsequently stimulate VICs [92]. Oxidized lipids directly stimulate VECs leading to increased expression of bone morphogenic protein (BMP) 2 and adhesion molecules, thereby promoting calcification and the recruitment of immune cells [55, 109, 146]. OxLDL can augment the osteogenic response of human VICs through modulation of the NF-κB pathway and NOTCH1 activation [171]. Furthermore, OxPLs are transformed into lysophosphatidylcholine (LysoPC) and subsequently into lysophosphatic acid (LPA) by Lp-PLA2 (lipoprotein-phospholipase A2), leading to apoptosis in VICs. LPA triggers an NF-κB-regulated inflammatory cascade in VICs and leads to increased expression of BMP2, IL-6 and Runt-related transcription factor 2 (Runx2) and secretion of alkaline phosphatase, stimulating valvular calcification [108, 130]. Additionally, LysoPC induces apoptosis in VICs [85]. In addition to Lp(a) and oxLDL, also triglyceride-rich lipoproteins are associated with an increased CAVD risk. Triglyceride-rich lipoproteins likely contribute to the lipid deposition and local inflammation by the release of monacylglycerols and free fatty acids [66].

OxPL play a similar role in the development of ASCVD. OxLDL induces endothelial dysfunction and activation, triggers the recruitment of circulating immune cells and foam cell formation, and stimulates the VSMC migration and proliferation in the atherosclerotic plaque. Furthermore, oxLDL contributes to the destabilization of the
atherosclerotic plaque by inducing apoptosis and the release of MMPs [116]. The OxPL on Lp(a) cause a proinflammatory monocyte response and inflammation of the arterial wall in humans [163].

**Beyond the valve: systemic inflammation and circulating immune cell activation**

There is accumulating evidence that CAVD, just like ASCVD, is characterized not only by local valvular inflammation, but also by low-grade systemic inflammation, although this is still controversial. In ASCVD, it is well established that elevated circulating levels of proinflammatory markers, e.g. IL-6 and high-sensitive C-reactive protein (hsCRP), are associated with major adverse cardiovascular events, which is independent of other traditional risk factors [68, 121, 124, 169]. Some studies also suggest an association between circulating hsCRP and the presence, severity and progression of CAVD [50, 88, 129], mostly in patients with advanced CAVD. Other studies, however, did not find a relationship between elevated hsCRP, the presence of aortic sclerosis or CAVD and disease progression [59, 106]. Also, no correlation was found between hsCRP and valvular inflammatory infiltrates [88]. The exact relationship between hsCRP levels and CAVD therefore remains uncertain. In a small observational study, patients with severe CAVD had increased levels of circulating TNF, but it is still not known whether this is causally related to CAVD pathophysiology or results from the haemodynamic consequences of CAVD [67]. More evidence points to activation of circulating innate immune cells in CAVD pathophysiology, which is highlighted below.

**Monocyte activation in CAVD**

Human monocytes can be divided in three subsets based on the surface expression of CD14 and CD16: classical monocytes are CD14++ CD16−, intermediate monocytes CD14++ CD16+ and non-classical monocytes are CD14+ CD16++ [141, 178]. In addition, other surface markers can be used to characterize subsets with specific functions. For example, classical monocytes are known for their high C–C chemokine receptor type 2 (CCR2) expression, whereas intermediate monocytes have high CCR5 expression [46, 141]. In general, circulating CD16+ monocytes, especially the intermediate monocytes, are associated with atherosclerotic disease [125, 155]. Few studies have characterized monocyte subsets in the setting of CAVD. Most of these studies are cross-sectional and observational in small patient groups, hence results need to be interpreted with caution. Shimoni et al. showed increased levels of CD14+ monocytes in patients with severe CAVD compared to controls which was inversely correlated with the aortic valve area surface [133]. Hewing et al. showed that patients with severe CAVD have higher levels of proinflammatory intermediate monocytes [59]. The level of intermediate monocytes has been reported to drop after aortic valve replacement (AVR) [60, 101], although the effect of the surgical intervention itself was not evaluated with a control group. The relationship between disease severity and monocyte subtypes is still unclear [59, 101]. It remains speculative whether the increased levels of circulating (intermediate) monocytes play a causal role in the pathophysiology of CAVD or, are rather a consequence of the disease through haemodynamic changes or valvular inflammation. Although these studies suggest that the phenotype of circulating monocytes is altered in patients with CAVD, more in-depth exploration of monocyte function and phenotype has not yet been performed.

Changes in monocyte phenotype have been described in the setting of ASCVD and also for several risk factors for CAVD. In patients with established CAD, circulating monocytes are characterized by an augmented cytokine production capacity [14, 134]. In addition, patients with elevated levels of Lp(a) show an increased level of intermediate monocytes, which correlates with OxPL/apoB, independent of circulating CRP and IL-6 [73]. Also, monocytes from patients with increased levels of LDL-cholesterol as well as Lp(a) show a hyperresponsive state, with an enhanced cytokine production capacity [13, 131, 163], which is associated with increased arterial wall inflammation in high Lp(a) conditions [163]. Circulating monocytes stem from bone marrow hematopoietic stem and progenitor cells. In patients with CAD, the bone marrow myeloid progenitor cells are programmed towards a proinflammatory phenotype [107]. This has never been investigated in the context of CAVD.

**Neutrophils: important players in CAVD?**

The role of neutrophils in cardiovascular inflammation and their possible contribution to the pathogenesis of CAVD only recently gained attention. Patients with severe CAVD have a higher absolute circulating neutrophil count compared to healthy controls [140]. An increased neutrophil-to-lymphocyte ratio is associated with the presence, severity and prognosis of CAVD [9, 26, 140]. In addition, Kopytek et al. demonstrated that calcified aortic valves exhibit significantly more neutrophil extracellular trap (NET) formation compared to healthy valves and that the amount of valvular NETs correlates with disease severity, suggesting a role for neutrophils in the progression of CAVD [70]. In contrast, by using electron microscopy, Kostyunin et al. did not find neutrophils to be present in severely calcified aortic valves [71]. More research is needed to identify the exact role of...
neutrophils in the fibro-calcific remodelling of the aortic valve.

The role of neutrophils and NETs in ASCVD is more established. A recent prospective epidemiological study demonstrated that circulating granulocyte count is strongly associated with the future occurrence of ASCVD [43]. Furthermore, an increased granulocyte-to-lymphocyte ratio is a risk factor for ASCVD [43]. Neutrophil activation and recruitment is promoted by chemokines, such as CC-chemokine ligand 5, during atherogenesis [135]. Activated neutrophils then secrete granule proteins, including Cathepsin G, at the luminal side, which can activate chemokines resulting in further myeloid cell recruitment. The secretion of ROS and myeloperoxidase, which mediates LDL oxidation and subsequently promotes foam cell formation, further promotes atherosclerotic disease progression [135]. Besides, neutrophils can promote vascular wall inflammation by the secretion of proinflammatory microvesicles [56] and the formation of NETs [35].

Proposed new mechanisms for circulating immune cell activation in CAVD

Until now, it is unclear how activation of innate immune cells might contribute to CAVD pathophysiology. Trained immunity and CHIP are recently described immunological mechanism that could potentially contribute to long-term activation of innate immune cells and we propose that these mechanisms could contribute to the development of ASCVD and CAVD (Fig. 3).

![Fig. 3](image-url) A schematic illustration of how systemic immune cell reprogramming can contribute to CAVD pathophysiology. Oxidative, mechanical or shear stress damages and activates valvular endothelial cells (VECs), altering endothelial permeability. This causes lipoproteins and immune cells to infiltrate the valvular tissue, creating an inflammatory environment. Local migrated immune cells and activated VECs and valvular interstitial cells (VICs) continue to stimulate each other, thereby causing chronic inflammation, fibrosis and calcification. This leads to valve leaflet stiffening and thickening, which increases mechanical stress, establishing a self-perpetuating cycle. Activation of innate immune cells, such as monocytes, macrophages and neutrophils, contributes to the initiation and development of CAVD. Risk factors for CAVD, such as hyperlipidaemia, elevated Lp(a) levels and a Western diet, activate hematopoietic stem and progenitor cells (HSPCs) and circulating immune cells. Trained immunity can lead to a persistent pro-inflammatory phenotype of circulating innate immune cells and myeloid progenitor cells. Clonal haematopoiesis of indeterminate potential (CHIP) results in a pro-inflammatory phenotype of HSPCs. The proinflammatory leukocytes infiltrate the valvular tissue and contribute to the development of CAVD by creating an inflammatory environment. The chronic inflammation that arises might in turn impact on HSPCs and circulating leukocytes.
Trained immunity

Trained immunity describes the phenomenon that innate immune cells, including monocytes and macrophages, are able to adapt their function after a first encounter with a DAMP or PAMP, leading to a long-term hyperresponsive phenotype [11]. Although this mechanism is beneficial in the context of recurrent infections, it might be detrimental in chronic inflammatory diseases in which these innate immune cells themselves contribute to pathobiology and tissue damage, such as atherosclerosis [45]. Trained immunity is dependent on intracellular metabolic and epigenetic reprogramming, resulting in a persistent proinflammatory phenotype, characterized by an increased cytokine production capacity [100]. In vitro, brief exposure of isolated human monocytes to oxLDL, Lp(a), uric acid or adrenaline/noradrenaline induces a trained macrophage phenotype [12, 161, 163].

Recent studies translated the concept of trained immunity to patients with established ASCVD or risk factors for ASCVD. In patients with CAD, the augmented cytokine production of circulating monocytes was associated with increased glycolysis and enrichment of epigenetic histone markers, characteristic of trained immunity [14]. In addition, monocytes from treatment-naïve patients with familial hypercholesterolaemia have an increased cytokine production capacity and enrichment of activating histone modifications on the promoters of these cytokine genes, which persisted for three months after cholesterol lowering with statins [13]. A similar hyperresponsive monocyte phenotype was observed in patients with elevated Lp(a) levels [163].

The prolonged presence of monocytes with a trained hyperresponsive phenotype is explained by the fact that training occurs at the level of myeloid precursors in the bone marrow [100]. In this regard, it was recently shown that isolated bone marrow mononuclear cells of patients with severe CAD demonstrate an increased cytokine production capacity and a higher metabolic rate than individuals without CAD. The bone marrow composition of the CAD patients showed skewing towards myelopoiesis and the hematopoietic stem and progenitor cells demonstrated enriched monocyte and neutrophil related pathways [107]. Moreover, several risk factors for both CAVD and ASCVD are described to reprogram myeloid progenitor cells in mouse models [28, 132, 167]. A Western type diet in Ldlr−/− mice induces long-term epigenetic and transcriptomic reprogramming of myeloid progenitor cells, leading to increased myelopoiesis and augmented innate immune responses, which persist despite switching back to a chow diet [28]. Furthermore, bone marrow transplantation from Western type diet fed Ldlr−/− mice into Ldlr−/− mice on a chow diet was associated with an increased number of circulating inflammatory leukocytes and an increased aortic root plaque sizes compared to chow fed donor bone marrow [167]. Similarly, transplantation of bone marrow progenitors from diabetic mice into normoglycemic atherosclerosis-prone mice accelerated atherosclerosis by trained immunity [41].

Clonal haematopoiesis and CAVD

Recently, clonal haematopoiesis of indeterminate potential (CHIP) has been identified as an important mechanism of innate immune cell activation [49, 64]. Clonal haematopoiesis (CH) describes the disproportionate clonal growth of leukocytes arising from a single progenitor cell harbouring a somatic mutation, without the presence of haematologic malignancy [142]. CH is rare in young patients, but the prevalence increases with age, affecting >10% of individuals older than 65 years [53, 170]. CH-driver mutations (CHDM) provide a survival advantage to the mutated cells and allow progressive clonal expansion, leading to accumulation of circulating mutant leukocytes [142]. CHDM occur mainly in genes encoding for epigenetic regulators, such as ten–eleven translocation 2 (TET2) and DNA methyltransferase 3A (DNMT3A). CH is associated with an augmented all-cause mortality risk [53, 63] and an increased risk of atherosclerotic CVD [49, 64]. At least for TET2 driver mutations, this association appears to be driven by a hyper-inflammatory phenotype of clonal monocytes. This is mediated, at least partly, due to the fact that TET2-deficient macrophages exhibit an increased NLRP3 inflammasome-dependent secretion of IL-1β [49], which is key to the development of atherosclerosis [123]. DNMT3A deficiency has been associated with diminished immunosuppressive function of myeloid-derived suppressor cells, proinflammatory activation of mast cells and an increased production of IFN-γ by T lymphocytes. However, a direct pathophysiological connection between DNMT3A loss-of-function and atherosclerosis has not yet been established [6]. Interestingly, it was demonstrated that increased haematological stem cell proliferation, driven by atherosclerosis itself, can accelerate CH, creating a vicious cycle [61].

Recently, in patients with severe CAVD undergoing transcatheter AVR, a higher prevalence of DNMT3A and TET2 mutations was found in circulating monocytes compared to other cohorts of healthy subjects or to subjects with CAD. Patients with CHDM had a markedly increased all-cause mortality during the first eight months after a successful transcatheter AVR. Compared to non-CHDM carriers, patients with TET2 mutations had elevated levels of proinflammatory non-classical monocytes and patients with DNMT3A mutations showed proinflammatory T lymphocyte polarization [87]. Moreover, another
study demonstrated that monocytes with severe degenerative aortic valve stenosis or chronic postischemic heart failure, who harbour DNMT3A or TET2 CHDM, appeared to be primed for excessive inflammatory responses by assessing the transcriptome of circulating peripheral monocytes of CAVD by single-cell RNA sequencing [2].

**Imaging of valvular inflammation and calcification**

Currently, echocardiography is used to clinically assess the severity of the aortic valve stenosis and computed tomography (CT) is used to quantify valvular macrocalcification and disease severity and progression [36]. However, it is important that we can properly measure inflammation, both systemically and locally, to obtain a better understanding of how inflammation contributes to CAVD pathophysiology. Active arterial wall inflammation can be visualized by 18F-fluorodeoxyglucose (18F-FDG) positron-emission tomography (PET) combined with CT [127]. In atherosclerotic plaques, FDG-uptake correlates with plaque macrophage burden [149]. Marincheva-Sancheva et al. were the first to demonstrate higher valvular 18F-FDG uptake in patients with mild and moderate CAVD, but not in patients with severe CAVD, compared to controls. This suggests that inflammation plays a more important role in the early phases of CAVD than in advanced disease. Also, patients with higher baseline 18F-FDG uptake showed an increased disease progression [86]. In addition, 18F-sodium fluoride (18F-NaF) PET–CT can be used, to detect recent calcification activity and calcium remodelling. Dweck et al. demonstrated that both valvular 18F-FDG and 18F-NaF uptake were higher in CAVD patients compared to controls. However, the 18F-NaF uptake displayed a more progressive rise with disease severity than the more modest increased uptake of 18F-FDG. Moreover, uptake of 18F-NaF and not 18F-FDG strongly correlates with disease severity [39]. A follow-up study demonstrated that both 18F-FDG and 18F-NaF uptake independently predict disease progression and adverse outcomes. 18F-NaF uptake correlates strongly with CT calcium score progression and novel calcium depositions develop in the same distribution as baseline 18F-NaF uptake. Interestingly, Abdelbacky et al. demonstrated that valvular 18F-FDG uptake independently predicted subsequent calcification in patients without CAVD at baseline and thus indicated that inflammation precedes calcification [1]. Together, these studies support that valvular inflammation plays an important role in early CAVD and precedes calcification, which predominantly drives disease progression in later stages. These findings correspond to recent findings in patients with atherosclerosis, showing mainly 18F-FDG uptake in arterial segments without advanced plaques, suggesting an arterial inflammatory state at early stages of atherosclerosis [44].

Finally, another emerging imaging technique in the imaging of CAVD patients is the use of PET combined with magnetic resonance imaging (MRI). In addition to the potential to detect valvular inflammation with tracers, the PET/MRI has particular added value in assessing prognostic factors, including characterization of the myocardial tissue for remodelling, fibrosis and hypertrophy [156].

**Pharmacological treatment to prevent severe CAVD**

Although CAVD can be diagnosed at an early stage, there is currently no effective medical treatment available and ‘watchful waiting’ is the only option until endovascular or surgical intervention is needed. Elucidation of the pathophysiology of CAVD will hopefully reveal potential pharmacological targets for prevention or treatment. Given the pivotal roles of (oxidized) lipoproteins, various trials have been performed with lipid-lowering drugs (Table 2). In addition, targeting systemic inflammation and the immune system might be an effective strategy to prevent or treat CAVD. For other examined agents in the search for a pharmacological treatment for CAVD, we refer to the recent review of Donato et al. [34].

**Lipid-lowering therapy**

The pivotal role of oxidized lipoproteins in CAVD suggest lipid-lowering as possible treatment. However, four double-blind randomized controlled trials (RCTs) showed that statins do not halt or slow down CAVD progression, in contrast to strong beneficial effects on ASCVD (Table 2) [23, 30, 32, 126]. This might be explained by the fact that these patients already had established CAVD with a self-perpetuating calcification process. Another explanation is that statins do not lower Lp(a), and can even increase Lp(a) levels [154]. Additionally, statins are suggested to increase vascular calcifications, which might increase plaque stability and reduce the number of cardiovascular events in the context of atherosclerosis [117, 122], but further drives calcification and subsequent disease progression in CAVD. Interestingly, a post hoc meta-analysis of three studies investigating the effect of 80 mg atorvastatin mg per day in patients with stable CVD without CAVD, did not show a reduced risk for developing CAVD [8]. However, two of the three included trials compared low-dose statin therapy as control; treatment naïve patients as control group may have resulted in different results.
| Trial         | Patients                                                                 | Study design                                      | Intervention                          | Primary + echocardiographic outcomes                                                                 | Inflammatory outcome                                              | Refs. |
|--------------|---------------------------------------------------------------------------|---------------------------------------------------|---------------------------------------|------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|-------|
| SALTIRE      | 155 patients with CAVD and aortic jet velocity ≥ 2.5 m/s                  | Double-blind, placebo-controlled RCT              | Atorvastatin 80 mg per day versus placebo | - Aortic jet velocity change/year<br>Atorvastatin: 0.199 ± 0.210 m/s<br>Placebo: 0.203 ± 0.208 m/s<br>($P = 0.95$)<br>- Calcification progression/year<br>Atorvastatin: 22.3 ± 21.0 %<br>Placebo: 21.7 ± 19.8 % ($P = 0.93$) | None mentioned                                                   | [30]  |
| TASS         | 47 patients with asymptomatic CAVD with mean systolic gradient ≥ 15 mmHg and peak velocity ≥ 2.0 m/s | Placebo-controlled RCT                             | Atorvastatin 20 mg per day versus placebo | - HR 0.78 (95% CI 0.32–1.87; $P = 0.569$) for MACE<br>- CAVD progression:<br>Mean gradient at last FU (mmHg):<br>Atorvastatin: 31.3 ± 12.3<br>Placebo: 29.9 ± 14.8 ($P = NS$)<br>Aortic valve calcification at last FU (Agatston score):<br>Atorvastatin: 2979 ± 1228<br>Placebo: 2749 ± 1376 ($P = NS$) | CRP level (mg/dl) 0.14 ± 0.66 in atorvastatin group versus 0.33 ± 1.39 in control group ($P < 0.05$) after 12 month FU.<br>$P = NS$ after 24 months FU | [32]  |
| SEAS         | 1873 patients with mild to moderate, asymptomatic CAVD                   | Multicentre, double-blind, placebo-controlled RCT | Simvastatin 40 mg + ezetimibe 10 mg per day versus placebo | - HR 0.96 (95% CI 0.83 to 1.12; $P = 0.59$) for MACE<br>- Increase in peak velocity (m/s): Simvastatin + ezetimibe: 0.61 ± 0.59<br>Placebo: 0.62 ± 0.61 ($P = 0.83$)<br>- Increase mean gradient (mmHg/year): Simvastatin + ezetimibe: 2.7 ± 0.1<br>Placebo: 2.8 ± 0.1<br>- Decrease in AVA (cm²/year): − 0.03 ± 0.01 in both groups | None mentioned                                                   | [126] |
| ASTRON-OMER  | 269 patients with mild or moderate CAVD                                  | Multicentre, double-blind, placebo-controlled RCT | Rosuvastatin 40 mg per day versus placebo | - Annualized peak AS gradient increase (mmHg):<br>Rosuvastatin: 6.3 ± 6.9<br>Placebo: 6.1 ± 8.2 ($P = 0.83$)<br>- Increase in mean gradient (mmHg):<br>Rosuvastatin: 10.7<br>Placebo: 9.6 ($P = 0.49$)<br>- Decrease in AVA (cm²): Rosuvastatin: − 0.19<br>Placebo: − 0.16 ($P = 0.79$) | CRP reduction of 0.33 mg/L in rosvastatin group compared to an increase of 0.095 mg/L in the placebo group ($P = 0.002$) | [23]  |
Convertase subtilisin/kexin type 9 (PCSK9) inhibitors are monoclonal antibodies that bind to circulating PCSK9 and inhibit PCSK9-mediated LDL-receptor degradation. This results in a powerful LDL-cholesterol lowering. In addition, PCSK9 inhibitors also lower Lp(a) concentration by 20–30% respectively [110, 128]. The FOURIER trial examined the effect of the PCSK9-inhibitor evolocumab in patients with stable atherosclerotic disease receiving statin therapy and demonstrated a reduced cardiovascular event risk [128]. Interestingly, a post hoc analysis of this trial displayed that treatment with evolocumab might also reduce CAVD related events [15], which is in line with the findings that patients with a PCSK9 loss-of-function mutation have a reduced CAVD risk [75]. These findings suggest that Lp(a) lowering might be able to prevent or slow down the progression of CAVD. These preliminary findings need further validation with RCTs and currently, the effects of PCSK9 inhibitors in CAVD are being investigated (Table 3) [157]. In addition, the effect of Lp(a) lowering on CAVD progression by niacin is being explored (Table 3) [158].

Another promising therapy targeting Lp(a) is antisense oligonucleotide therapy. These synthetic oligonucleotides bind to apoB or apo(a) mRNA in hepatocytes, resulting in a decreased production of apoB-containing lipoproteins and Lp(a). This leads to a significant reduction in circulating OxPL and Lp(a) [168]. Currently, the HORIZON trial, a large phase 3 multicentre RCT is recruiting patients to assess the impact of the antisense oligonucleotide TQJ230 on major cardiovascular events in patients with CVD (Table 3) [160]. This therapy might also be beneficial in patients with CAVD.

### Anti-inflammatory agents

To the best of our knowledge, there are no clinical trials investigating the effect of anti-inflammatory drugs on CAVD. In the setting of ASCVD, however, recently several RCTs have reported effectiveness of the anti-inflammatory drugs colchicine and canakinumab in the prevention of CVD, following the publication of many neutral trials with other anti-inflammatory drugs [175]. Given the overlap in inflammatory components in the pathophysiology of atherosclerotic CVD and CAVD, these drugs might also have beneficial effects in the context of CAVD.

The low-dose colchicine for secondary prevention of cardiovascular disease (LoDoCo) trial demonstrated that colchicine, a broad anti-inflammatory agent, reduces the risk of cardiovascular events in patients with stable CAD [104]. This beneficial effect was confirmed in two large RCTs in patients after recent myocardial infarction [148], or with chronic coronary disease [105]. In addition to its known inhibitory effect on inflammasome activation, colchicine appears to attenuate neutrophil activation [112]. Given these actions, colchicine might be an attractive candidate to limit
The Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) demonstrated that inhibition with the human anti-IL-1β antibody canakinumab decreases cardiovascular event rates in patients with a recent myocardial infarction [123]. This trial did not evaluate the effects on CAVD. Nonetheless, IL-1β production by macrophages induces calcification by vascular mesenchymal cells [22], which makes IL-1β also an interesting candidate for CAVD treatment. Furthermore, the CHIP-associated aberrant inflammation, such as the IL-1β overexpression by TET2 deficient macrophages, further strengthens the possible role for IL-1β as therapeutic target in CAVD [49]. As a consequence of the promising results of the CANTOS trial, attention has moved upstream of the IL-1β pathway to target inflammasomes and downstream IL-6. Animal studies using NLRP3 inflammasome inhibitors and IL-6 receptor antagonists have shown promising results in targeting atherosclerosis [4, 162, 166], but larger trials are needed to investigate their clinical relevance.

Conclusion

In conclusion, evidence is gradually accumulating that the complex pathophysiology of CAVD is an inflammatory process in which various immune cells plays a prominent role. Considering the central role of innate immune cells in the pathophysiology of ASCVD and the similarities between ASCVD and CAVD, it is rational to hypothesize that activation of the innate immune system also contributes to the initiation and progression of CAVD. Further elucidation of the driving processes of innate immune cell activation in CAVD, including trained immunity and CHIP, might identify novel therapeutic targets that can be used for prevention and treatment of CAVD. The recent exciting evidence that anti-inflammatory strategies potently limits atherosclerotic CVD further underscores the importance of this scientific field.

Acknowledgements The figures were designed using BioRender.

Author contributions All listed authors contributed significantly to the submitted work. W.B. drafted the manuscript and figures; SB, SEM, LABJ, NR and NPR contributed substantially to the discussion of its contents and reviewed and edited the manuscript before submission. NPR and NR secured funding.

Funding This work was supported by an IN-CONTROL CVON grant (CVON2018-27) and a grant of the ERA-CVD Joint Transnational Call 2018, which is supported by the Dutch Heart Foundation in the Hague (JTC2018, project MEMORY; 2018T093). S.B. is supported by the Dutch Heart Foundation in the Hague (Dekker grant 2018-T028).

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval No ethical approval was obtained as this a review paper. As for the relationship with the industry, L.A.B.J. is founder of Trained Therapeutix Discovery.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes...
were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Abdelbaky A, Corsini E, Figueroa AL, Subramanian S, Fontanaz S, Emami H, Hoffmann U, Narula J, Tawakol A (2015) Early aortic valve inflammation precedes calcification: a longitudinal FDG-PET/CT study. Atherosclerosis 238:165–172. https://doi.org/10.1016/j.atherosclerosis.2014.11.026
2. Abplanalp WT, Mas-Peiro S, Cremer S, John D, Dimmeler S, Zeiher AM (2020) Association of clonal hematopoiesis of indeterminate potential with inflammatory gene expression in patients with severe degenerative aortic valve stenosis or chronic postischemic heart failure. JAMA Cardiol 5:1170–1175. https://doi.org/10.1001/jamacardiol.2020.2468
3. Aikawa E, Nahrendorf M, Sosnovik D, Lok VM, Jaffer FA, Aikawa M, Weissleder R (2007) Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation 115:377–386. https://doi.org/10.1161/circulationaha.106.654913
4. Aikita K, Isoda K, Sato-Okabayashi Y, Kadoguchi T, Kitamura K, Ohimoto F, Shimada K, Daida H (2017) An interleukin-6 receptor antibody suppresses atherosclerosis in athergenic mice. Front Cardiovasc Med 4:84. https://doi.org/10.3389/fcvm.2017.00084
5. Allara E, Morani G, Carter P, Gkatzionis A, Zuber V, Foley CN, Rees JMB, Mason AM, Bell S, Gill D, Lindström S, Butterworth CVR/CVAB2 73
6. Amoros-Perez M, Fuster JJ (2020) Clonal hematopoiesis driven by somatic mutations: a new player in atherosclerotic cardiovascular disease. Atherosclerosis 297:120–126. https://doi.org/10.1016/j.atherosclerosis.2020.02.008
7. Arsenault BJ, Boekholdt SM, Dube MP, Rheume E, Wareham NJ, Khaw KT, Sandhu MS, Tardif JC (2014) Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet 7:304–310. https://doi.org/10.1161/circgenetics.113.000400
8. Arsenault BJ, Boekholdt SM, Mora S, DeMicco DA, Bao W, Tardif JC, Ambrosio P, Pedersen T, Barter P, Waters DD (2014) Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). Am J Cardiol 113:1378–1382. https://doi.org/10.1016/j.amjcard.2014.01.414
9. Avci A, Elnur A, Goksel A, Serdar F, Servet I, Atilla K, Mustafa TM, Cuneyt T, Yeliz G, Mustafa B, Metin EA (2014) The relationship between neutrophil/lymphocyte ratio and calcific aortic stenosis. Echocardiography 31:1031–1035. https://doi.org/10.1111/echo.12534
10. Bartoli-Leonard F, Zimmer J, Aikawa E (2021) Innate and adaptive immunity: the understudied driving force of heart valve disease. Cardiovasc Res 117:2506–2524. https://doi.org/10.1093/cvr/cvab273
11. Bekkering S, Dominguez-Andrés J, Joosten LAB, Riksen NP, Netea MG (2021) Trained immunity: reprogramming innate immunity in health and disease. Annu Rev Immunol 39:667–693. https://doi.org/10.1146/annurev-immunol-102119-073855
12. Bekkering S, Quintin J, Joosten LA, van der Meer JW, Netea MG, Riksen NP (2014) Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes. Arterioscler Thromb Vasc Biol 34:1731–1738. https://doi.org/10.1161/atvbaha.114.303887
13. Bekkering S, Stiekelma LCA, Bernetol Moens S, Verweij SL, Novakovic B, Prange K, Versluit M, Roeters van Lennep JE, Stunnenberg H, de Winter M, Stroes ESG, Joosten LAB, Netea MG, Riksen NP (2019) Treatment with statins does not revert trained immunity in patients with familial hypercholesterolemia. Cell Metab 30:1–2. https://doi.org/10.1016/j.cmet.2019.05.014
14. Bekkering S, van den Munckhof I, Nielen T, Lamfers E, Dinarello C, Rutten J, de Graaf J, Joosten LA, Netea MG, Gomes ME, Riksen NP (2016) Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo. Atherosclerosis 254:228–236. https://doi.org/10.1016/j.atherosclerosis.2016.10.019
15. Bergmark BA, O’Donoghue ML, Murphy SA, Kuder JF, Ezhov MV, Cséka R, Gouni-Berthold I, Jensen HK, Tok og ozgo lu SL, Mach F, Huber K, Gaci o nz G, Lewis BS, Schiele F, Jukema JW, Pedersen TR, Giugliano RP, Sabatine MS (2020) An Exploratory analysis of proprotein convertase subtilisin/kexin type 9 inhibition and aortic stenosis in the FOURIER trial. JAMA Cardiol 5:709–713. https://doi.org/10.1001/jamacardio.2020.0728
16. Bonow RO, Greenland P (2015) Population-wide trends in aortic stenosis incidence and outcomes. Circulation 131:969–971. https://doi.org/10.1161/circulationaha.115.014846
17. Boring L, Gosling J, Cleary M, Charo IF (1998) Decreased lesion calcification by regulating macrophage interleukin-1β production. Nature 394:894–897. https://doi.org/10.1038/29788
18. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342. https://doi.org/10.1038/nature01658
19. Butcher JT, Mahler GJ, Hockaday LA (2011) Aortic valve disease and treatment: the need for naturally engineered solutions. Adv Drug Deliv Rev 63:242–268. https://doi.org/10.1016/j.addr.2011.01.008
20. Capoulade R, Chan KL, Yeang C, Mathieu P, Bosse Y, Dumesnil JG, Tam JW, Teo KK, Mahmut A, Yang X, Witztum JL, Arsenault BJ, Despres JP, Pibarot P, Tsimikas S (2015) Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol 66:1236–1246. https://doi.org/10.1016/j.jacc.2015.07.020
21. Capoulade R, Yeang C, Chan KL, Pibarot P, Tsimikas S (2018) Association of mild to moderate aortic valve stenosis progression with higher lipoprotein(a) and oxidized phospholipid levels: secondary analysis of a randomized clinical trial. JAMA Cardiol 3:1212–1217. https://doi.org/10.1001/jamacardio.2018.3798
22. Ceneri N, Zhao L, Young BD, Healy A, Coskun S, Vasavada AJ, Martino N, Wiltse D, Schiller NL, Khaw KT, Sandhu MS, Tardif JC, Amarenco P, Pedersen T, Barter P, Waters DD (2014) Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve disease. Cardiovasc Res 117:2506–2524. https://doi.org/10.1093/cvr/cvab273
23. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J (2010) Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation:
measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 121:306–314. https://doi.org/10.1161/circulationaha.109.900027

24. Chávez-Sánchez L, Madrid-Miller A, Chávez-Rueda K, Legorreta-Huquet MV, Tesoro-Cruz E, Blanco-Favela F (2010) Activation of TLR2 and TLR4 by minimally modified low-density lipoprotein in human macrophages and monocytes triggers the inflammatory response. Hum Immunol 71:737–744. https://doi.org/10.1016/j.humimm.2010.05.005

25. Chen JH, Yip CY, Sone ED, Simmons CA (2009) Identification of aortic valve mesenchymal progenitor cells with robust osteogenic calcification potential. Am J Pathol 174:1109–1119. https://doi.org/10.2353/ajpath.2009.080750

26. Cho KI, Her AY, Singh GB, Shin ES (2016) Prognostic utility of neutrophil-to-lymphocyte ratio on adverse clinical outcomes in patients with severe calcific aortic stenosis. PLoS ONE 11:e0161530. https://doi.org/10.1371/journal.pone.0161530

27. D’Ascenzo F, Conrotto F, Giordana F, Moretti C, D’Amico Dichtl W, Alber HF, Feuchtner GM, Hintringer F, Reinthaler 03. 062

28. Christ A, Gunther P, Lauterbach MAR, Dwewell P, Biswas D, Pelka K, Scholz CJ, Oosting M, Haendler K, Bassler K, Klee K, Schulte-Schrepping J, Ulas T, Moorlag S, Kumar V, Park MH, Joosten LAB, Groh LA, Riksen NP, Espevik T, Schlüchter A, Li Y, Fitzgerald ML, Netea MG, Schulze JL, Latz E (2018) Western diet triggers NLRP3-dependent innate immune reprogramming. Cell 172:162–175.e114. https://doi.org/10.1016/j.cell.2017.12.013

29. Cote N, Mahmut A, Bosse Y, Couture C, Page S, Trahan S, Boulangar MC, Fournier D, Pibarot P, Mathieu P (2013) Inflammation is associated with the remodeling of calcific aortic valve disease. Inflammation 36:573–581. https://doi.org/10.1007/s10573-012-9579-6

30. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA (2005) A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352:2389–2397. https://doi.org/10.1056/NEJMoa043876

31. D’Ascenzo F, Conrotto F, Giordana F, Moretti C, D’Amico M, Salizzoni S, Omedè P, La Torre M, Thomas M, Khawaja 10. 3390/ijms21218263

32. Donato M, Ferri N, Lupo MG, Faggini E, Rattazzi M (2020) Current evidence and future perspectives on pharmacological treatment of calcific aortic valve stenosis. Int J Mol Sci 21:8263. https://doi.org/10.3390/ijms21218263

33. Dweck MR, Boon NA, Newby DE (2012) Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol 60:1854–1863. https://doi.org/10.1016/j.jacc.2012.02.093

34. Dweck MR, Jones C, Joshi NV, Fletcher AM, Richardson H, White A, Marsden M, Pessotto R, Clark JC, Wallace WA, Salter DM, McKillop G, van Beek EJ, Boon NA, Rudd JH, Newby DE (2012) Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation 125:76–86. https://doi.org/10.1161/CIRCULATIONAHA.111.051052

35. Edep ME, Shirani J, Wolf P, Brown DL (2000) Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovasc Pathol 9:281–286. https://doi.org/10.1016/s1054-8807(00)00043-0

36. Edgar L, Akbar N, Braithwaite AT, Krausgruber T, Gallart-Ayala H, Bailey J, Corbin AL, Khoyratty TE, Chai JT, Alkalhi M, Rendeiro AF, Ziberna K, Arya R, Cahiil TJ, Bock C, Lauc rrencienci e J, Crabtree MJ, Lemieux ME, Riksen NP, Netea MG, Wheelock CE, Channon KM, Rydén M, Udalova IA, Car nicker R, Choudhry RP (2021) Hyperglycemia induces trained immunity in macrophages and their precursors and promotes atherosclerosis. Circulation 144:961–982. https://doi.org/10.1161/ circulationaha.120.046464

37. Durham AL, Speer MY, Scatena M, Giachelli CM, Shanahan 0016/j.jacc.2018.12.075

38. Evrard SM, Lecce L, Michelis KC, Nomura-Kitabayashi A, Pandey G, Purushothaman KR, d’Escamard V, Li JR, Hadri L, Fujitani K, Moreno PR, Benard L, Rimpele P, Cohain A, Mecham B, Randolph GJ, Nabel EG, Hajjar R, Fuster V, Boehm M, Kovacic JC (2016) Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability. Nat Commun 7:11853. https://doi.org/10.1038/ncomms11853

39. Fanti L, van der Willik KD, Bos D, Leening MJG, Koudstaal PJ, Rizopoulos D, Rutter R, Stricker BHC, Kavousi M, Ikram MA, Ikram MK (2020) The association of innate and adaptive immunity, subclinical atherosclerosis, and cardiovascular disease in the Rotterdam Study: a prospective cohort study. PLoS Med 17:e1003115. https://doi.org/10.1371/journal.pmed.1003115

40. Fernández-Friera L, Fuster V, López-Melgar B, Oliva B, Sánchez-González J, Macías A, Pérez-Aseyo B, Zamudio D, Alonso-Farto JC, España S, Mendiguren J, Bueno H, García-Ruiz JM, Ibañez B, Fernández-Ortiz A, Sanz J (2019) Vascular inflammation in subclinical atherosclerosis detected by hybrid PET/MRI. J Am Coll Cardiol 73:1371–1382. https://doi.org/10.1016/j.jacc.2018.12.075

41. Flores-Gomez D, Bekkering S, Netea MG, Riksen NP (2021) Trained immunity in atherosclerotic cardiovascular disease. Arterioscler Thromb Vasc Biol 41:62–69. https://doi.org/10.1161/ atvbaha.120.314216

42. Franca CN, Izar MCO, Hertencio MNS, do Amaral JB, Rizopoulos D, Rutter R, Stricker BHC, Kavousi M, Ikram MA, Ikram MK (2020) The association of innate and adaptive immunity, subclinical atherosclerosis, and cardiovascular disease in the Rotterdam Study: a prospective cohort study. PLoS Med 17:e1003115. https://doi.org/10.1371/journal.pmed.1003115

43. Freeman RV, Otto CM (2022) Basic Research in Cardiology (2022) 117:28. https://doi.org/10.1161/circresaha.120.315931

44. Freeman RV, Otto CM (2022) Basic Research in Cardiology (2022) 117:28. https://doi.org/10.1161/circresaha.120.315931

45. García-Ruiz JM, Ibañez B, Fernández-Ortiz A, Sanz J (2019) Vascular inflammation in subclinical atherosclerosis detected by hybrid PET/MRI. J Am Coll Cardiol 73:1371–1382. https://doi.org/10.1016/j.jacc.2018.12.075

46. García-Ruiz JM, Ibañez B, Fernández-Ortiz A, Sanz J (2019) Vascular inflammation in subclinical atherosclerosis detected by hybrid PET/MRI. J Am Coll Cardiol 73:1371–1382. https://doi.org/10.1016/j.jacc.2018.12.075

47. García-Ruiz JM, Ibañez B, Fernández-Ortiz A, Sanz J (2019) Vascular inflammation in subclinical atherosclerosis detected by hybrid PET/MRI. J Am Coll Cardiol 73:1371–1382. https://doi.org/10.1016/j.jacc.2018.12.075
48. Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A (2015) Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385:1397–1405. https://doi.org/10.1016/s0140- 6736(14)61368-4

49. Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, Wu CL, Sano S, Muralidharan S, Rius C, Vuong J, Jacob S, Muralidhar V, Robertson AA, Cooper MA, Andres V, Hirschi KK, Martin KA, Walsh K (2017) Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 355:842–847. https://doi.org/10.1126/science.aag1381

50. Galante A, Pietroini A, Vellini M, Piccolo P, Possati G, De Bonis M, Grillo RL, Fontana C, Favalli C (2001) C-reactive protein is increased in patients with degenerative aortic valve stenosis. J Am Coll Cardiol 38:1078–1082. https://doi.org/10.1016/s0735- 1097(01)01484-x

51. Galeone A, Brunetti G, Oranger A, Greco G, Di Benedetto A, Mori G, Colucci S, Zallone A, Paparella D, Grano M (2013) Aortic valvar interstitial cells apoptosis and calcification are mediated by TNF-related apoptosis-inducing ligand. Int J Cardiol 169:296–304. https://doi.org/10.1016/j.ijcard.2013.09.012

52. García-Rodríguez C, Parra-Izquierdo I, Castanos-Mollor I, López J, San Roman JA, Sanchez Crespo M (2018) Toll-like receptors, inflammation, and calcific aortic valve disease. Front Physiol 9:201. https://doi.org/10.3389/fphys.2018.00201

53. Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoun SF, Chambert K, Mick E, Neale BM, Frimer M, Purcell SM, Svaness O, Landen M, Hoglund M, Lehmann S, Gabriel SB, Moran JL, Lander ES, Sullivan PF, Sklar P, Gronberg H, Hultman CM, McCarrol SA (2014) Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371:2477–2487. https://doi.org/10.1056/NEJMoa1409405

54. Getz GS, Reardon CA (2012) Animal models of atherosclerosis. Arterioscler Thromb Vasc Biol 32:1104–1115. https://doi.org/10.1161/ATVBAHA.111.237693

55. Ghiasas NK, Foley JB, O’Brien DS, Crean P, Kelleher D, Walsh M (2000) Adhesion molecules in nonrheumatic aortic valve disease: endothelial expression, serum levels and effects of valve replacement. J Am Coll Cardiol 36:2257–2262. https://doi.org/10.1016/0735-1097(00)00998-0

56. Gomez I, Ward B, Souilhol C, Recarti C, Ariaans M, Johnston JM, Cheek D, Iwamoto Y, Schloss MJ, Vandosorne K, Ibora-Egea O, Muñoz-Guijosa C, Bayes-Genis A, Reiter JG, Craig M, Swirsiki FK, Nahrendorf M, Nowak MA, Naxeroxova K (2021) Increased stem cell proliferation in atherosclerosis accelerates clonal hematopoiesis. Cell 184:1348-1361.e1322. https://doi.org/10.1016/j.cell.2021.01.049

57. Jackson V, Eriksson MJ, Caidahl K, Eriksson P, Franco-Cereceda A (2014) Ascending aortic dilatation is rarely associated with coronary artery disease regardless of aortic valve morphology. J Thorac Cardiovasc Surg 148:2973–2980.e2971. https://doi.org/10.1016/j.jtcvs.2014.08.023

58. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsey RC, Mermel CH, Burtt N, Chavez A, Higgins JM, Molchanov V, Kuo FC, Kluk MJ, Henderson B, Kimunnen L, Koistinen HA, Lademall C, Getz G, Correa A, Banahan BF, Gabriel S, Kathiresan S, Stringham HM, McCarthy MI, Boehnke M, Tuomilehto J, Haiman C, Groop L, Azmoun G, Wilson JG, Neuberg D, Altschuler D, Ebert BL (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371:2488–2498. https://doi.org/10.1056/NEJMoa1408617

59. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, Baber U, Mehran R, Fuster V, Danesh J, Frossard P, Saledeen D, Melander O, Sukhova GK, Neuberg D, Libby P, Kathiresan S, Ebert BL (2017) Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 377:111–121. https://doi.org/10.1056/NEJMoa1701719

60. Kaden JJ, Bickelhaupt S, Groholz R, Haase KK, Sarikoç A, Kilic R, Brueckmann M, Lang S, Zahn I, Vahl C, Hagi S, Dempfle CE, Borggrefe M (2004) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 36:57–66. https://doi.org/10.1016/j.yjmcc.2003.09.015

61. Kaltoft M, Langsted A, Nordestgaard BG (2020) Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study. Eur Heart J 41:2288–2299. https://doi.org/10.1093/eurheartj/ehaa172

62. Kapadia SR, Yakooob K, Nader S, Thomas JD, Mann DL, Griff Bin BP (2000) Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. J Am Coll Cardiol 36:208–212. https://doi.org/10.1016/s0735-1097(00)00721-x

63. Kappoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J (2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375:132–140. https://doi.org/10.1016/s0140-6736(09)61717-7

64. Kavurma MM, Rayner KJ, Karunakaran D (2017) The walking dead: macrophage inflammation and death in atherosclerosis. Curr Opin Lipidol 28:91–98. https://doi.org/10.1097/mol.0000000000000394

65. Kaden JJ, Bickelhaupt S, Groholz R, Haase KK, Sarikoç A, Kilic R, Brueckmann M, Lang S, Zahn I, Vahl C, Hagi S, Dempfle CE, Borggrefe M (2004) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 36:57–66. https://doi.org/10.1016/j.yjmcc.2003.09.015

66. Kaltoft M, Langsted A, Nordestgaard BG (2020) Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study. Eur Heart J 41:2288–2299. https://doi.org/10.1093/eurheartj/ehaa172

67. Kapadia SR, Yakooob K, Nader S, Thomas JD, Mann DL, Griff Bin BP (2000) Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. J Am Coll Cardiol 36:208–212. https://doi.org/10.1016/s0735-1097(00)00721-x

68. Kappoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J (2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375:132–140. https://doi.org/10.1016/s0140-6736(09)61717-7

69. Kavurma MM, Rayner KJ, Karunakaran D (2017) The walking dead: macrophage inflammation and death in atherosclerosis. Curr Opin Lipidol 28:91–98. https://doi.org/10.1097/mol.0000000000000394

70. Kopystek M, Kolasa-Trela R, Zabczyk M, Undas A, Natorska J (2019) NETosis is associated with the severity of aortic stenosis:

71. Springer
71. Kostyunin A, Mukhamadiyarov R, Glushkova T, Bogdanov L, Shishkova D, Osysaev N, Ovcharenko E, Kutikhin A (2020) Ultra-structural pathology of atherosclerosis, calcific aortic valve disease, and bioprosthetic heart valve degeneration: commonalities and differences. Int J Mol Sci 21:7434. https://doi.org/10.3390/ijms21207434

72. Kostyunin AE, Yuzhalin AE, Ovcharenko EA, Kutikhin AG (2019) Development of calcific aortic valve disease: do we know enough for new clinical trials? J Mol Cell Cardiol 132:189–209. https://doi.org/10.1016/j.yjmcc.2019.05.016

73. Krychtuk KA, Kastl SP, Hofbauer SL, Wonnerth A, Goliash G, Oszvar-Kozma M, Katsaros KM, Maurer G, Huber K, Dostal E, Binder CJ, Pfaefflenberger S, Oravec S, Wojta J, Speidl WS (2015) Monocyte subtype distribution in patients with stable atherosclerosis and elevated levels of lipoprotein(a). J Clin Lipidol 9:533–541. https://doi.org/10.1016/j.jacl.2015.04.005

74. Kvidal P, Bergström R, Hörte LG, Ståhle E (2000) Observed and relative survival after aortic valve replacement. J Am Coll Cardiol 35:747–756. https://doi.org/10.1016/S0735-1097(00)00584-7

75. Langsted A, Nordestgaard BG, Benn M, Tybjærg-Hansen A, Ceravolo R, Bevilacqua S, Glauber M, Biagini A, Tanganelli P (2006) Biological features (inflammation and neoangiogenesis) and atherosclerotic risk factors in carotid plaques and calcified aortic valve stenosis: two different sites of the same disease? Am J Clin Pathol 126:494–502. https://doi.org/10.1309/w75nte5qce9dx603

76. Latif N, Quillon A, Sarathchandra P, McCormack A, Lozanoski A, Vaouby MH, Chester AH (2015) Modulation of human valvular interstitial cells and immune cells. Immune Netw 16:26–32. https://doi.org/10.1371/journal.pone.0127844

77. Lee SH, Choi JH (2016) Involvement of immune cell network in aortic valve stenosis: communication between valvular interstitial cells and immune cells. Immune Netw 16:26–32. https://doi.org/10.4110/in.2016.16.1.26

78. Li C, Xu S, Gotlieb AI (2013) The progression of calcific aortic valve disease through injury, cell dysfunction, and disruptive biologic and physical force feedback loops. Cardiovasc Pathol 22:1–8. https://doi.org/10.1016/j.carpath.2012.06.005

79. Li G, Qiao W, Zhang W, Li F, Shi J, Dong N (2017) The shift of macrophages toward M1 phenotype promotes aortic valvular calcification. J Thorac Cardiovasc Surg 153:1318-1327.e1317. https://doi.org/10.1093/jtcvs/2016.1206

80. Libby P (2021) The changing landscape of atherosclerosis. Nature 592:524–533. https://doi.org/10.1038/s41586-021-03392-8

81. Libby P (2021) The changing landscape of atherosclerosis. Nature 592:524–533. https://doi.org/10.1038/s41586-021-03392-8

82. Libby P (2021) Inflammation during the life cycle of the atherosclerotic plaque. Cardiovasc Res 117:2525–2536. https://doi.org/10.1093/cvr/cvab303

83. Lindman BR, Clavel MA, Mathieu P, Jung B, Lancellotti P, Otto CM, Pibarot P (2016) Calcific aortic stenosis. Nat Rev Dis Primers 2:16006. https://doi.org/10.1038/ndrprim.2016.6

84. Lintefsky J, Katz R, Budoff M, Probstfield J, Owens D, Takasu J, Shavelle D, Ouyang P, Psaty B, O’Brien KD (2011) Stage of systemic hypertension and blood pressure as correlates of computed tomography-assessed aortic valve calcium (from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol 107:47–51. https://doi.org/10.1016/j.amjcard.2010.08.042

85. Mahler GJ, Farrar EJ, Butcher JT (2013) Inflammatory cytokines promote mesenchymal transformation in embryonic and adult valve endothelial cells. Arterioscler Thromb Vasc Biol 33:121–130. https://doi.org/10.1161/ATVBAHA.112.300504

86. Mahmoud A, Boulanger MC, El Husseinii D, Fournier D, Bouchereb R, Despres JP, Pibarot P, Bosse Y, Mathieu P (2014) Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization. J Am Coll Cardiol 63:460–469. https://doi.org/10.1016/j.jacc.2013.05.105

87. Marincheva-Savcheva G, Subramanian S, Qadir S, Figueroa A, Truong Q, Vijayakumar J, Brady TJ, Hoffmann U, Tawakol A (2011) Imaging of the aortic valve using fluoro deoxyglucose positron emission tomography increased valvular fluordeoxyglucose uptake in aortic stenosis. J Am Coll Cardiol 57:2507–2515. https://doi.org/10.1016/j.jacc.2010.12.046

88. Mas-Perio S, Hoffmann J, Fichtlscherer S, Dorsher A, Wier A, Dimmeler S, Vasa-Nicotera M, Zeimer AH (2020) Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation. Eur Heart J 41:933–939. https://doi.org/10.1093/eurheartj/ehz591

89. Mazzone A, Epistolato MC, De Caterina R, Storti S, Vittorini S, Sbrana S, Gianetti J, Bevilacqua S, Glauber M, Biagini A, Tanganelli P (2004) Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. J Am Coll Cardiol 43:1670–1676. https://doi.org/10.1016/j.jacc.2003.12.041

90. Mazzone A, Epistolato MC, Gianetti J, Castagnini M, Sassi C, Ceravolo R, Bevilacqua S, Glauber M, Biagini A, Tanganelli P (2006) Biological features (inflammation and neoangiogenesis) and atherosclerotic risk factors in carotid plaques and calcified aortic valve stenosis: two different sites of the same disease? Am J Pathol 126:494–502. https://doi.org/10.1309/w75nte5qce9dx603

91. Miller JD, Weiss RM, Serrano KM, Berry CJ, Zimmerman K, Young SG, Heistad DD (2009) Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation 119:2693–2701. https://doi.org/10.1161/circulationaha.108.834614

92. Miteva K, Madonna R, De Caterina R, Van Linthout S (2018) Innate and adaptive immunity in atherosclerosis. Vascul Pharmacol 107:67–77. https://doi.org/10.1016/j.vph.2018.04.006

93. Mohler ER 3rd, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS (2001) Bone formation and inflammation in cardiovascular calcification. J Thorac Cardiovasc Surg 135:1318–1327.e1311. https://doi.org/10.1532/jvcs.2017.01.052

94. Mohty D, Pibarot P, Despres JP, Cote C, Arsenault B, Cartier A, Cosnay P, Couture C, Mathieu P (2008) Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 28:187–193. https://doi.org/10.1161/ATVBAHA.107.154989

95. Moore KJ, Sheedy FJ, Fisher EA (2013) Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol 13:709–721. https://doi.org/10.1038/ni3520

96. Nadlovec N, Lee JH, Reece TB, Weyant MJ, Cleveland JC Jr, Meng X, Fullerton DA (2013) Interleukin-1 Beta induces an inflammatory phenotype in human aortic valve interstitial cells through nuclear factor kappa Beta. Ann Thorac Surg 96:155–159. https://doi.org/10.1016/j.athoracsur.2013.04.013

97. Nagy E, Eriksson P, Yousry M, Caidahl K, Ingelsson E, Hansson GK, Franco-Cereceda A, Back M (2013) Valvular osteoclasts in calcification and aortic valve stenosis severity. Int J Cardiol 168:2264–2271. https://doi.org/10.1016/j.ijcard.2013.01.207

98. Nagy E, Lei Y, Martinez-Martinez E, Body SC, Schlottter F, Creager M, Assmann A, Khabbaz K, Libby P, Hansson GK, Aikawa E (2017) Interferon-gamma released by activated CD8(+) T lymphocytes impairs the calcium resorption potential of osteoclasts.
in calcified human aortic valves. Am J Pathol 187:1413–1425. https://doi.org/10.1016/j.ajpath.2017.02.012
99. Natorska J, Marek G, Sadowski J, Undas A (2016) Presence of B cells within aortic valves in patients with aortic stenosis: relation to severity of the disease. J Cardiol 67:80–85. https://doi.org/10.1016/j.jcc.2015.05.002
100. Netea MG, Dominguez-Andres J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mihrang MM, Mulder WJM, Riksen NP, Schlitzer A, Schultze JL, Stabeli Benn C, Sun Jc, Xavier RJ, Latz E (2020) Defining trained immunity and its role in health and disease. Nat Rev Immunol 20:375–388. https://doi.org/10.1038/s41577-020-0285-6
101. Neuser J, Galuppo P, Fraccarollo D, Willig J, Kempf T, Berliner D, Bauersachs J, Widder JD (2017) Intermediate CD14++CD16+ monocytes decline after transcatheter aortic valve replacement and correlate with functional capacity and left ventricular systolic function. PLoS ONE 12:e0183670. https://doi.org/10.1371/journal.pone.0183670
102. New SE, Aikawa E (2011) Molecular imaging insights into early inflammation and its role in health and disease. J Cardiol 67:80–85. https://doi.org/10.1161/journal.pone.0183670
103. Newby AC (2008) Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 28:2108–2114. https://doi.org/10.1161/atvbaha.108.173898
104. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL (2013) Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 61:404–410. https://doi.org/10.1016/j.jacc.2012.10.027
105. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu XF, Ireland MA, Lenderink T, Latcham D, Hoogslag P, Jerzewski A, Nierop P, Henkens C, Bax WA, Dirksen M, Alings MMW, Hendriks C, Bax WA, Dirkens M, Alings MMW, Hankey GJ, Budgeon CA, Tijsjen JGP, Cornel JH, Thompson PL (2020) Colchicine in patients with chronic coronary disease. N Engl J Med 383:1838–1847. https://doi.org/10.1056/NEJMoa2021372
106. Novaro GM, Katz R, Aviles RJ, Gottdiener JS, Cushman M, Psaty BM, Otto CM, Prendergast B (2014) Aortic-valve stenosis—from patients at risk to severe valve obstruction. N Engl J Med 371:744–756. https://doi.org/10.1056/NEJMra1313875
107. Olsson M, Thyberg J, Nilsson J (1999) Presence of oxidized low density lipoprotein in calcified human aortic valves. Arterioscler Thromb Vasc Biol 19:1218–1222. https://doi.org/10.1161/01.atv.19.5.1218
108. Opstal TSJ, Hoogeveen RM, Fiolet ATL, Silvis MJM, The SHK, Bax WA, de Kleijn DPV, Mosterd A, Stroes ESG, Cornel JH (2020) Colchicine attenuates inflammation beyond the inflammasome in chronic coronary artery disease: a LoDoCo2 proteomic substudy. Circulation 142:1996–1998. https://doi.org/10.1161/circulationaha.118.037184
109. O’Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Češka R, Ezhev MV, Jukema JW, Jensen HK, Tokgozolu SL, Mach F, Huber K, Sever PS, Kechch AC, Pedersen TR, Sabatine MS (2019) Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation 139:1483–1492. https://doi.org/10.1161/circulationaha.118.037184
110. Olsson M, Thyberg J, Nilsson J (1999) Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 19:1218–1222. https://doi.org/10.1161/01.atv.19.5.1218
111. O’Brien KD (1994) Characterization of the early lesion of “degenerative” valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90:844–853. https://doi.org/10.1161/jcir.90.2.844
112. Opstal TSJ, Hoogeveen RM, Fiolet ATL, Silvis MJM, The SHK, Bax WA, de Kleijn DPV, Mosterd A, Stroes ESG, Cornel JH (2020) Colchicine attenuates inflammation beyond the inflammasome in chronic coronary artery disease: a LoDoCo2 proteomic substudy. Circulation 142:1996–1998. https://doi.org/10.1161/circulationaha.118.037184
113. Otsu CM, Kuusisto J, Reichenbach DD, Gown AM, O’Brien KD (1994) Characterization of the early lesion of “degenerative” valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90:844–853. https://doi.org/10.1161/jcir.90.2.844
114. Peeters F, Meex S, Dweck MR, Aikawa E, Crijns H, Schurgers LJ, Krietelei B (2018) Calcific aortic valve stenosis: hard disease in the heart: a biomolecular approach towards diagnosis and treatment. Eur Heart J 39:2618–2624. https://doi.org/10.1093/eurheartj/ehx653
115. Pirillo A, Norata GD, Catapano AL (2013) LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm 2013:152786. https://doi.org/10.1155/2013/152786
116. Pirillo A, Norata GD, Catapano AL (2013) LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm 2013:152786. https://doi.org/10.1155/2013/152786
117. Puri R, Nicholls SJ, Shao M, Kataoka Y, Uno K, Kapadia SR, Tuzcu EM, Nissen SE (2015) Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol 65:1273–1282. https://doi.org/10.1016/j.jacc.2015.01.036
118. Raddatz MA, Madhurst MS, Merryman WD (2019) Adaptive immune cells in calcific aortic valve disease. Am J Physiol Heart Circ Physiol 317:H141-h155. https://doi.org/10.1152/ajpheart.00100.2019
119. Rajammann NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, Simmons CA, Masters KS, Mathieu P, O’Brien KD, Schoen FJ, Towler DA, Yoganathan AP, Otto CM (2011) Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update. Circulation 124:1783–1791. https://doi.org/10.1161/CIRCULATIONAHA.110.006767
120. Richards J, El-Hamamsy I, Chen S, Sarang Z, Sarathchandra P, Yacoub MH, Chester AH, Butcher JT (2013) Side-specific endothelial-dependent regulation of aortic valve calcification: interplay of hemodynamics and nitric oxide signaling. Am J Pathol 182:1922–1931. https://doi.org/10.1016/j.ajpath.2013.01.037
121. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973–979. https://doi.org/10.1056/nejm199704033361401
122. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koening W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207. https://doi.org/10.1056/NEJMoa0807646
report. Arterioscler Thromb Vasc Biol 37:1457–1461. https://doi.org/10.1161/ATVBAHA.117.309575

163. van der Valk FM, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul JD, Ravandi A, Nederveen AJ, Verberne HJ, Scipione C, Nieuwpoort M, Joostena LA, Netea MG, Koschinsky ML, Witzum JL, Tsimakas S, Riksøn NP, Stroes ES (2016) Oxidized phospholipids on lipoprotein(a) elicited arterial wall inflammation and an inflammatory monocyte response in humans. Circulation 134:611–624. https://doi.org/10.1161/CIRCULATIONAHA.116.020838

164. van der Valk FM, Kuijck C, Verweij SL, Stiekema LCA, Kaiser Y, Zeerleder S, Nahrendorf M, Voermans C, Stroes ESG (2017) Increased haematopoietic activity in patients with atherosclerosis. Eur Heart J 38:425–432. https://doi.org/10.1093/europace/ehw246

165. van Geemen D, Soares AL, Oomen PJ, Diressen-Mol A, Jansen-van den Broek MW, van den Bogaardt AJ, Bogers AJ, Goumans MJ, Baaijens FP, Bouten CV (2016) Age-dependent changes in geometry, tissue composition and mechanical properties of fetal to adult cryopreserved human heart valves. PLoS ONE 11:e0149202. https://doi.org/10.1371/journal.pone.0149202

166. van Hout GP, Bosch L, Ellenbrook GH, de Haan JJ, van Solinge WW, Cooper MA, Arslan F, de Jager SC, Robertson AA, Pasterkamp G, Hoeter JE (2017) The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. Eur Heart J 38:828–836. https://doi.org/10.1093/eurheartj/ehw247

167. van Kampen E, Jaminon A, van Berkel TJ, Van Eck M (2014) Diet-induced (epigenetic) changes in bone marrow augment atherosclerosis. J Leukoc Biol 96:833–841. https://doi.org/10.1189/jlb.1A0114-017R

168. Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witzum JL, Stroes ES, Tsimakas S (2016) Anti-sense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388:2239–2253. https://doi.org/10.1016/S0140-6736(16)31009-1

169. Volpato S, Guralnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, Harris TB (2001) Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women’s health and aging study. Circulation 103:947–953. https://doi.org/10.1161/01.cir.103.7.947

170. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendt MC, Michaelson JF, Schmidt HK, Yelepantula V, Miller CA, Ozeneberger BA, Welch JS, Link DC, Walter MJ, Mardis ER, Dipersio JF, Chen F, Wilson RK, Ley TJ, Ding L (2014) Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20:1472–1478. https://doi.org/10.1038/nm.3733

171. Zeng Q, Song R, Ao L, Xu D, Venardos N, Fullerton DA, Meng X (2014) Augmented osteogenic responses in human aortic valve cells exposed to oxLDL and TLR4 agonist: a mechanistic role of Notch1 and NF-kB interaction. PLoS ONE 9:e95400. https://doi.org/10.1371/journal.pone.0095400

172. Zeng Q, Song R, Fullerton DA, Ao L, Zhai Y, Li S, Ballak DB, Cleveland JC Jr, Reece TB, McKinsey TA, Xu D, Dinarello CA, Meng X (2017) Interleukin-37 suppresses the osteogenic responses of human aortic valve interstitial cells in vitro and alleviates valve lesions in mice. Proc Natl Acad Sci U S A 114:1631–1636. https://doi.org/10.1073/pnas.1619667114

173. Zhan Q, Zeng Q, Song R, Zhai Y, Xu D, Fullerton DA, Dinarello CA, Meng X (2017) IL-37 suppresses MyD88-mediated inflammatory responses in human aortic valve interstitial cells. Mol Med 23:83–91. https://doi.org/10.2119/molmed.2017.00022
174. Zhang P, The E, Nedumaran B, Ao L, Jarrett MJ, Xu D, Fuller-ton DA, Meng X (2020) Monocytes enhance the inflammatory response to TLR2 stimulation in aortic valve interstitial cells through paracrine up-regulation of TLR2 level. Int J Biol Sci 16:3062–3074. https://doi.org/10.7150/ijbs.49332

175. Zhao TX, Mallat Z (2019) Targeting the immune system in atherosclerosis: JACC state-of-the-art review. J Am Coll Cardiol 73:1691–1706. https://doi.org/10.1016/j.jacc.2018.12.083

176. Zheng KH, Tsimikas S, Pawade T, Kroon J, Jenkins WSA, Doris MK, White AC, Timmers N, Hjortnaes J, Rogers MA, Aikawa E, Arsenault BJ, Witztum JL, Newby DE, Koschinsky ML, Fayad ZA, Stroes ESG, Boekholdt SM, Dweck MR (2019) Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J Am Coll Cardiol 73:2150–2162. https://doi.org/10.1016/j.jacc.2019.01.070

177. Zheng KH, Tzolos E, Dweck MR (2020) Pathophysiology of aortic stenosis and future perspectives for medical therapy. Cardiol Clin 38:1–12. https://doi.org/10.1016/j.ccl.2019.09.010

178. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu YJ, MacPherson G, Randolph GJ, Scherberich J, Schmitz J, Shortman K, Sozzani S, Strobl H, Zembala M, Austyn JM, Lutz MB (2010) Nomenclature of monocytes and dendritic cells in blood. Blood 116:e74-80. https://doi.org/10.1182/blood-2010-02-258558